Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of “Buy” from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $36.50.

A number of research firms have recently commented on BCAX. HC Wainwright upped their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday. Finally, Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Wednesday, February 12th.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX opened at $12.42 on Tuesday. The company has a fifty day moving average price of $13.19. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Spire Wealth Management bought a new position in shares of Bicara Therapeutics in the fourth quarter valued at $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $33,000. Summit Investment Advisors Inc. purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $35,000. Finally, Virtus ETF Advisers LLC purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $69,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.